Clover Health Investments Corp. Cl A (CLOV): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLOV POWR Grades
- CLOV scores best on the Quality dimension, with a Quality rank ahead of 54.77% of US stocks.
- The strongest trend for CLOV is in Growth, which has been heading down over the past 179 days.
- CLOV ranks lowest in Stability; there it ranks in the 2nd percentile.
CLOV Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CLOV is 7.68 -- better than 95.17% of US stocks.
- CLOV's price/sales ratio is 0.19; that's higher than the P/S ratio of merely 5.18% of US stocks.
- As for revenue growth, note that CLOV's revenue has grown 149.54% over the past 12 months; that beats the revenue growth of 94.44% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CLOVER HEALTH INVESTMENTS CORP are JUPW, TIRX, EEIQ, TRC, and SGLY.
- CLOV's SEC filings can be seen here. And to visit CLOVER HEALTH INVESTMENTS CORP's official web site, go to www.cloverhealth.com.
CLOV Valuation Summary
- CLOV's price/earnings ratio is -1.4; this is 106.03% lower than that of the median Healthcare stock.
- CLOV's price/sales ratio has moved down 1.3 over the prior 32 months.
Below are key valuation metrics over time for CLOV.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CLOV | 2022-11-25 | 0.2 | 1.6 | -1.4 | -0.6 |
| CLOV | 2022-11-23 | 0.2 | 1.5 | -1.3 | -0.5 |
| CLOV | 2022-11-22 | 0.2 | 1.5 | -1.4 | -0.5 |
| CLOV | 2022-11-21 | 0.2 | 1.5 | -1.3 | -0.5 |
| CLOV | 2022-11-18 | 0.2 | 1.6 | -1.4 | -0.6 |
| CLOV | 2022-11-17 | 0.2 | 1.6 | -1.4 | -0.6 |
CLOV's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CLOV has a Quality Grade of C, ranking ahead of 33.49% of graded US stocks.
- CLOV's asset turnover comes in at 1.618 -- ranking 5th of 133 Insurance stocks.
- 500 - Internal server error
The table below shows CLOV's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 1.618 | 0.009 | -0.991 |
| 2021-03-31 | 1.251 | 0.098 | -0.276 |
| 2020-12-31 | 1.398 | 0.148 | -0.223 |
| 2020-09-30 | 1.222 | 0.222 | 0.038 |
| 2020-09-30 | 0.000 | NA | -0.006 |
CLOV Price Target
For more insight on analysts targets of CLOV, see our CLOV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.00 | Average Broker Recommendation | 2.3 (Moderate Sell) |
CLOV Stock Price Chart Interactive Chart >
CLOV Price/Volume Stats
| Current price | $1.36 | 52-week high | $4.80 |
| Prev. close | $1.33 | 52-week low | $1.21 |
| Day low | $1.27 | Volume | 5,185,200 |
| Day high | $1.37 | Avg. volume | 10,000,055 |
| 50-day MA | $1.52 | Dividend yield | N/A |
| 200-day MA | $2.43 | Market Cap | 650.00M |
Clover Health Investments Corp. Cl A (CLOV) Company Bio
Clover Health Investments, Corp. provides health insurance services. The company was founded in 2012 and is based in Franklin, Tennessee.
Latest CLOV News From Around the Web
Below are the latest news stories about CLOVER HEALTH INVESTMENTS CORP that investors may wish to consider to help them evaluate CLOV as an investment opportunity.
6 Penny Stocks to Sell Right Now … And 1 to BuyDon't be tempted by the ultra-low price of these penny stocks. |
Clovis Oncology (CLVS) Stock Pops After Bankruptcy WarningToday, speculators are bidding up shares of Clovis Oncology and CLVS stock, after the company announced bankruptcy concerns. |
7 Penny Stocks Smart Investors Shouldn’t Touch With a 10-Foot PoleDon't let the recent bull market rally fool you into thinking these seven penny stocks to avoid are worthwhile moonshots. |
Clover Health Reports Third Quarter 2022 Financial ResultsThird quarter Insurance MCR of 86.3% and year-to-date Insurance MCR of 91.7% demonstrate positive momentum The Company updates 2022 full year guidance to include improved 2022 Insurance MCR range of 93% to 94% Clover intends to continue to grow Insurance business at above-market rates in 2023 but will moderate growth to prioritize profitability Company outlines strategic reduction in number of ACO REACH participating physicians in 2023; targeting Non-Insurance MCR below 100% The Company reports |
Clover Health to Present at Credit Suisse 31st Annual Healthcare Conference on November 10, 2022FRANKLIN, Tenn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today announced that its CEO, Vivek Garipalli, will present at the Credit Suisse 31st Annual Healthcare Conference on Thursday, November 10, 2022, at 12:10 p.m. Eastern Time. A live webcast of the presentation will be accessible from Clover Health's investor relations websi |
CLOV Price Returns
| 1-mo | -4.23% |
| 3-mo | -43.57% |
| 6-mo | -46.03% |
| 1-year | -68.37% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -63.44% |
| 2021 | -77.82% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...